ENV-201 / Endeavor BioMed - LARVOL DELTA

The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib (AACR-NCI-EORTC 2022) - "ENV-201-mediated ULK1 inhibition thus shows promise as both a single agent or in combination with a growth factor/RAS/MAPK pathway-targeting cancer treatment."

Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline (Businesswire) - "Endeavor BioMedicines...announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.... Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers....Endeavor plans to complete IND-enabling studies and advance the...ENV-201...program into the clinic in the next year."

Financing • New trial • Oncology

Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program from Salk Institute and Sanford Burnham Prebys to Broaden Its Precision Oncology Pipeline (Businesswire) - “Endeavor BioMedicines…announced the in-licensing of a ULK1/2 inhibitor program from the Salk Institute for Biological Studies and Sanford Burnham Prebys. The license agreement provides Endeavor with exclusive worldwide rights to ENV-201, an orally available small molecule inhibitor of ULK1/2, a critical enzyme in a cellular recycling process called autophagy that is often linked to drug resistance in RAS- and LKB1-mutated cancers. Endeavor plans to complete IND-enabling studies and advance the program into the clinic initially in colorectal and lung cancers in the next 18 months…In preclinical models, the ULK1/2 inhibitor ENV-201 demonstrated single-agent activity against these tumors providing a potential therapeutic option where there is none today.”

Licensing / partnership • Preclinical